Abstract
Aim DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.
Methods Sitagliptin (100 mg) was administered to 47 healthy volunteers. Several endpoints were measured to assess clinically relevant responses – including the effect of sitagliptin on glucose and insulin levels during an oral glucose tolerance test (OGTT).
Results This pilot study confirmed that sitagliptin (100 mg) decreased the area under the curve for glucose during an OGTT (p=0.0003). Furthermore, sitagliptin promoted insulin secretion during the early portion of the OGTT as reflected by an increase in the ratio of plasma insulin at 30 min divided by plasma insulin at 60 min (T30:T60) from 0.87+/-0.05 to 1.62+/-0.36 mU/L (p=0.04). The magnitude of sitagliptin’s effect on insulin secretion (as judged by the increase in the T30:T60 ratio for insulin) was correlated with the magnitude of sitagliptin-induced increase in the area under the curve for intact plasma GLP1 levels during the first hour of the OGTT. This study confirmed previously reported sex differences in glucose and insulin levels during an OGTT. Specifically, females exhibited higher levels of glucose and insulin at the 90-180 min time points. However, we did not detect significant sex-associated differences in the magnitude of sitagliptin-induced changes in T30:T60 ratios for either glucose or insulin.
Conclusions T30:T60 ratios for insulin and glucose during an OGTT provide useful indices to assess pharmacodynamic responses to DPP4 inhibitors.
Competing Interest Statement
SIT serves as a consultant for Ionis Pharmaceuticals. As an inventor, SIT receives a share of royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an employee of Regeneron Genetics Center. BDM and MEM receive grant support from Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support from funds provided by RGC. ALB, ZSY, and HRC declare no competing interests.
Clinical Trial
NCT05762744
Funding Statement
American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease (P30DK072488, P30DK079637, T32DK098107)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board at the University of Maryland Baltimore
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease (P30DK072488, P30DK079637, T32DK098107)
Trial registration: NCT05762744 (clinicaltrials.gov)
Study review and approval: Institutional Review Board of the University of Maryland Baltimore
Revised language to improve clarity.
Data Availability
Data will be made available to qualified academic researchers subject to terms specified in a Data Transfer Agreement to protect confidential information of participants.
